Early Izokibep (IL17Ai) data demonstrated clinically meaningful, dose-dependent improvement across PROs, particularly sleep, pain, function ,+ SF36 and PsAID subdomains in PsA pts. Pts w/ baseline enthesitis had greater benefit. Abs 0199 #ACR22 @RheumNow https://t.co/sXVdwGPVnd https://t.co/Cxyfp6OXOY